Biotechnology USA-based Amgen, the world's largest independent biotech firm, says that the US Food and Drug Administration has granted Breakthrough Therapy designation to investigational bispecific T cell engager (BiTE) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia. 1 July 2014